At the end of the year the fund "take medicine" to supplement the pharmaceutical tap was snubbed

On November 6th Hengrui Pharma rose another 5.21 per cent, its share price hit an all-time high, and its market capitalisation climbed to $200bn, while Fosun Pharma followed in the footsteps, with a total market capitalisation of $100bn. No. 1 financial note, with the implementation of health care reform-related policies gradually landed, since October, the pharmaceutical industry has risen significantly. Since the fourth quarter, after the liquor stocks hit new highs, "drinking and taking medicine" in the pharmaceutical theme fund has also opened a pull-up model.
the close of trading on November 6th, china's medical and health index rose 3.13 per cent in a single day, the third straight session of gains and more than 10 per cent in the last three months, according to Wind data. Industry insiders expect the rise in the pharmaceutical sector to continue, driven by improved performance and a rebound in the ultra-fall. However, in the context of a more serious stock differentiation, institutions are more optimistic about the "strong Hengqiang" leading varieties.
, however, for this prejudgment, some fund managers have come forward to question it! There are fund managers on the pharmaceutical stocks began to pick and choose, and the pharmaceutical leader has been snubbed.
Foreign Finance found that Penghua's fund tracking the index - Penghua China Securities Medical and Health Index Fund three months of cumulative net worth growth rate of 11.92 percent, surpassing the CSI 300 during the same period 8.45 percent increase. Cui Junjie, fund manager of the fund, believes that in the sector leader Hengrui Pharmaceuticals and Yunnan White Pharmaceuticals continue to record high background, some fundamentals are good, the growth logic of the second-tier pharmaceutical stocks may gradually become the focus of institutional positions.
" aging is one of the important logics for the long-term increase of investment and development of medicine in China. Cui Junjie thinks. Data show that by 2020, China's over-60s are expected to reach 248 million people, accounting for 17.5% of the total population. With the problem of aging becoming more and more serious, President Xi Jinping said in his report to the 19th National Congress on October 18, 2017 that the implementation of the Healthy China Strategy, actively respond to the aging of the population, build a policy system and social environment for the elderly, filial piety and respect for the elderly, promote the integration of medical care, accelerate the cause of aging and industrial development. The implementation of the future healthy aging strategy may bring sustained benefits to the pharmaceutical sector. In the short term, since October, the major fund companies have published three quarterly reports, public funds on the pharmaceutical sector allocation ratio is low, the current willingness to add funds to medicine is still strong.
also noted that the overall earnings of listed companies in the pharmaceutical sector are improving, and the business climate of the pharmaceutical industry continues to improve. According to Guojin Securities Li Jinglei statistics, in the first three quarters of 2017, the pharmaceutical sector (excluding new shares) sales revenue, operating profit and net profit growth were 19.95%, 22.58% and 31.20%, respectively. Excluding API, the pharmaceutical sector (excluding new shares) reported sales revenue, operating profit and net profit growth of 20.59%, 23.58% and 33.63%, respectively.
should I buy pharmaceutical stocks? Is the timing right? While investors are still struggling with these questions, Penghua Fund gives the answer: buy a pharmaceutical-themed fund. As of November 6, 29, or 72.5 percent, had yields of more than 4 percent in the past month, according to Wind. Among them, Penghua Pharmaceutical Science and Technology rose 11.55 percent in the past month, leading the industry, index fund Penghua China Securities Medical and Health, but also a package of investment in 74 pharmaceutical and health-related component stocks, to avoid investors to choose stocks. (Sina)